Myalept

Active Ingredient(s): Metreleptin
FDA Approved: * February 24, 2014
Pharm Company: * AMYLIN PHARMS LLC

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Myalept Overview

Metreleptin (trade names Myalept, Myalepta) is a synthetic analog of the hormone leptin used to treat diabetes and various forms of dyslipidemia. It has been approved in Japan for metabolic disorders including lipodystrophy and in the United States as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy.[1] In Europe based on EMA, metreleptin should be used in a...

Read more Myalept Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Metreleptin

Recent Myalept Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Metreleptin

Injection: 11.3mg

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Myalept: (2 results)

Sorted by National Drug Code

66780-310 Myalept 11.3 mg/2.2ml Subcutaneous Injection, Powder, Lyophilized, for Solution by Amylin Pharmaceuticals, LLC
76431-210 Myalept 11.3 mg/2.2ml Subcutaneous Injection, Powder, Lyophilized, for Solution by Aegerion Pharmaceuticals, Inc.

Other drugs which contain Metreleptin or a similar ingredient: (1 result)

METRELEPTIN